Table 1.
Patient characteristics of 540 newly diagnosed multiple myeloma patients grouped in four time-periods depending on the time of diagnosis
| Parameter | Cohort 1 1996–2005 n = 71 |
Cohort 2 2006–2010 n = 125 |
Cohort 3 2011–2015 n = 191 |
Cohort 4 2016–2019 n = 153 |
|---|---|---|---|---|
| Median age, | 57 | 59 | 59 | 62 |
| years (range) | (31–70) | (41–70) | (29–71) | (40–75) |
| ECOG 0/1, n (%) | 45 (81) | 85 (71) | 98 (52) | 97 (64) |
| ≥ 2, n (%) | 10 (19) | 34 (29) | 92 (48) | 55 (36) |
| Unavailable, n | 16 | 6 | 1 | 1 |
| MM-Type | ||||
| IgG, n (%) | 43 (61) | 62 (50) | 99 (52) | 80 (52) |
| IgA, n (%) | 11 (15) | 28 (22) | 37 (19) | 36 (24) |
| IgD, n (%) | 0 | 1 (1) | 1 (1) | 2 (2) |
| Light chain, n (%) | 15 (21) | 26 (21) | 53 (28) | 34 (22) |
| Asecretory, n (%) | 2 (3) | 8 (6) | 1 (1) | 1 (1) |
| ISS | ||||
| I, n (%) | 24 (61) | 66 (54) | 94 (49) | 78 (51) |
| II, n (%) | 8 (21) | 28 (23) | 59 (31) | 45 (29) |
| III, n (%) | 7 (18) | 28 (23) | 38 (20) | 30 (20) |
| Unavailable, n | 32 | 3 | 0 | 0 |
| Cytogeneticsa | ||||
| High-riskb, n (%) | 0 | 8 (13) | 33 (23) | 38 (32) |
| Standard-risk, n (%) | 16 (100) | 52 (87) | 110 (77) | 81 (68) |
| Unavailable, n | 55 | 65 | 48 | 34 |
| Transplant methodsc | ||||
| Single ASCT, n (%) | 40 (56) | 62 (50) | 158 (83) | 134 (86) |
| Tandem ASCT, n (%) | 6 (8) | 49 (39) | 12 (6) | 15 (10) |
| Auto-RICallo-SCT, n (%) | 25 (35) | 14 (11) | 21 (11) | 4 (3) |
| Maintenance (IMiDs), n (%) | 4 (6) | 7 (6) | 27 (14) | 75 (49) |
| Median PFS (months) | 39 | 36 | 39 | 43 |
| Median OS (months) | 80 | 78 | 74 | nr |
Abbreviation: nr not reached
a Results available from 338 patients
b High-risk: del(17p), t(4;14), t(14;16), t(16;20)
cSingle ASCT: n = 394, tandem ASCT n = 82, auto-RICallo-SCT n = 64